[Use of glurenorm in patients with non-insulin-dependent diabetes mellitus and liver diseases].
Due to its pharmacokinetics, glurenorm (95% of the drug metabolite is withdrawn from the body with the bile) is widely used in patients with non-insulin-dependent diabetes mellitus (NIDDM) with disturbed renal function. It seemed that, bearing in mind the relationship between glurenorm elimination and liver function, this drug use in patients with NIDDM patients with liver diseases should be restricted. The aim of the present research was to study glurenorm effect on liver function. Eighteen patients with NIDDM and liver diseases, administered glurenorm, were followed up. No clinical or laboratory deterioration on the part of the liver were detected over the course of follow-up. The results evidence no negative effects of glurenorm on the kidneys or liver, therefore the drug may be used in the treatment of NIDDM patients with liver abnormalities.
Dedov
I I
II
Demidova
I Iu
IIu
Pisklakov
S V
SV
Antokhin
E A
EA
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008107:Liver Diseases / Q000097:blood / Q000150:complications*; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D001786:Blood Glucose; D002096:C-Peptide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C010969:gliquidone
Primenenie gliurenorma u bol'nykh insulinnezavisimym sakharnym diabetom s zabolevaniiami pecheni.